Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Triflusal vs. aspirin

This article was originally published in The Tan Sheet

Executive Summary

Aspirin and anti-clotting drug triflusal are similarly effective in secondary stroke prevention but triflusal poses less hemorrhage risk, according to two studies presented. Triflusal, an antiplatelet agent structurally related to aspirin, was developed in Spain about 20 years ago and is licensed for use in parts of Europe, Asia and Latin America; approval never has been sought in the U.S., according to the American Stroke Association. One study of 429 patients was conducted in Buenos Aires, Argentina; another trial looked at 2,108 patients in Spain and Portugal. Both compared the efficacy of triflusal 600 mg to aspirin 325 mg among subjects who had suffered a recent TIA or stroke

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts